Epic Sciences Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
90
- Latest Deal Type
-
2ndary - Private
- Investors
-
10
Epic Sciences General Information
Description
Developer of diagnostic tests technology designed for quick and non-invasive detection of genetic and molecular changes in cancer. The company's technology assesses the number of circulating tumor cells and their subtypes, profiles single-cell phenotype and genotype as well as provides near real-time information about each different cellular population before and after treatments with no cell left behind, enabling oncologists to identify and analyze rare disease cells from a tube of blood that also contains millions of normal cells.
Contact Information
Website
www.epicsciences.comCorporate Office
- 9381 Judicial Drive
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 9381 Judicial Drive
- Suite 200
- San Diego, CA 92121
- United States
Epic Sciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 17. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 16. Later Stage VC (Series G) | 27-Feb-2023 | Completed | Generating Revenue | |||
| 15. Later Stage VC (Series F) | 29-Apr-2022 | Completed | Generating Revenue | |||
| 14. Secondary Transaction - Private | 01-Feb-2021 | Completed | Generating Revenue | |||
| 13. Debt - PPP | 14-Apr-2020 | Completed | Generating Revenue | |||
| 12. Later Stage VC (Series E) | 12-Sep-2018 | Completed | Generating Revenue | |||
| 11. Debt - General | 01-Aug-2017 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series D) | 28-Apr-2017 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series C1) | 23-May-2016 | $6.74M | $69M | Completed | Generating Revenue | |
| 8. Debt - General | 01-Jun-2015 | $15M | $62.3M | Completed | Generating Revenue |
Epic Sciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series G-2 | ||||||||
| Series G-1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Epic Sciences Comparisons
Industry
Financing
Details
Epic Sciences Competitors (24)
One of Epic Sciences’s 24 competitors is Agena Bioscience, a Formerly PE-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agena Bioscience | Formerly PE-Backed | San Diego, CA | ||||
| RareCyte | Venture Capital-Backed | Seattle, WA | ||||
| Foundation Medicine | Formerly VC-backed | Boston, MA | ||||
| Lunaphore | Formerly VC-backed | Tolochenaz, Switzerland | ||||
| Agendia | Venture Capital-Backed | Irvine, CA |
Epic Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Epic Sciences Patents
Epic Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4445141-A1 | Enhanced characterization of breast cancer | Pending | 07-Dec-2021 | ||
| US-20230175073-A1 | Enhanced characterization of breast cancer | Inactive | 07-Dec-2021 | ||
| WO-2023107566-A1 | Enhanced characterization of breast cancer | Inactive | 07-Dec-2021 | ||
| JP-2023120213-A | Methods of detecting therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease | Pending | 02-Jun-2017 | ||
| AU-2018275265-A1 | Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease | Inactive | 02-Jun-2017 | G01N33/57555 |
Epic Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Epic Sciences Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Minogue Consulting | Venture Capital | Minority | ||
| Blue Ox Healthcare Partners | Growth/Expansion | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Labcorp Venture Fund | Corporate Venture Capital | Minority | ||
| Varian | Corporation | Minority |
Epic Sciences FAQs
-
When was Epic Sciences founded?
Epic Sciences was founded in 2008.
-
Where is Epic Sciences headquartered?
Epic Sciences is headquartered in San Diego, CA.
-
What is the size of Epic Sciences?
Epic Sciences has 90 total employees.
-
What industry is Epic Sciences in?
Epic Sciences’s primary industry is Diagnostic Equipment.
-
Is Epic Sciences a private or public company?
Epic Sciences is a Private company.
-
What is Epic Sciences’s current revenue?
The current revenue for Epic Sciences is .
-
How much funding has Epic Sciences raised over time?
Epic Sciences has raised $243M.
-
Who are Epic Sciences’s investors?
Minogue Consulting, Blue Ox Healthcare Partners, Deerfield Management, Labcorp Venture Fund, and Varian are 5 of 10 investors who have invested in Epic Sciences.
-
Who are Epic Sciences’s competitors?
Agena Bioscience, RareCyte, Foundation Medicine, Lunaphore, and Agendia are some of the 24 competitors of Epic Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
